MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-28-2026
Novartis AG Current Ratio 2011-2026 | NVS
Annual Current Ratio Novartis AG
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.72 | 1.76 | 1.88 | 2.02 | 2.06 | 1.8 | 1.88 | 2.18 | 2.26 | 1.12 | 0.964 | 1.39 | 1.16 | 1.16 | 1.04 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.26 | 0.964 | 1.63 |
Quarterly Current Ratio Novartis AG
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 2.05 | - | 2.06 | - | 1.77 | - | 1.8 | - | 1.77 | - | 1.88 | - | 1.79 | - | 2.18 | - | 2.18 | - | 2.26 | - | - | - | 2.36 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.36 | 1.77 | 2.01 |
Current Ratio of other stocks in the Biotechnology industry
| Issuer | Current Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Apellis Pharmaceuticals
APLS
|
1.52 | $ 20.41 | -1.4 % | $ 2.57 B |  USA |
 |
MorphoSys AG
MOR
|
1.02 | - | 2.43 % | $ 254 M |  Germany |
 |
Aptorum Group Limited
APM
|
3.71 | $ 0.79 | -6.51 % | $ 4.31 M |  China |
 |
Axsome Therapeutics
AXSM
|
1.15 | $ 165.07 | -0.79 % | $ 8.21 B | USA |
 |
I-Mab
IMAB
|
8.96 | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.59 | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
1.34 | - | -13.47 % | $ 169 M |  France |
 |
AbCellera Biologics
ABCL
|
3.48 | $ 3.76 | -1.7 % | $ 1.12 B |  Canada |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.02 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
2.29 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Burford Capital Limited
BUR
|
2.14 | $ 8.57 | -1.83 % | $ 1.4 B | Britain |
 |
Corvus Pharmaceuticals
CRVS
|
6.63 | $ 18.11 | 1.23 % | $ 870 M | USA |
 |
Adverum Biotechnologies
ADVM
|
1.65 | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.04 | - | - | - |  Russia |
 |
ARCA biopharma
ABIO
|
28.7 | - | 1052.0 % | $ 415 M | USA |
 |
Acer Therapeutics
ACER
|
0.41 | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
2.67 | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
1.61 | - | -24.86 % | $ 820 K | USA |
 |
Capricor Therapeutics
CAPR
|
1.63 | $ 26.36 | -1.82 % | $ 706 M | USA |
 |
Certara
CERT
|
3.15 | $ 7.24 | 2.62 % | $ 1.16 B | USA |
 |
Acasti Pharma
ACST
|
13.4 | - | 4.01 % | $ 150 M | Canada |
 |
Codexis
CDXS
|
1.82 | $ 1.01 | -0.98 % | $ 74.1 M | USA |
 |
CureVac N.V.
CVAC
|
2.47 | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
1.6 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
1.81 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
12.4 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.79 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
6.48 | - | 1.93 % | $ 17.4 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
7.37 | $ 23.77 | -0.46 % | $ 2.91 B | USA |
 |
Agenus
AGEN
|
0.708 | $ 3.27 | -2.09 % | $ 1.17 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
6.43 | - | - | $ 7.46 M |  Israel |
 |
Akero Therapeutics
AKRO
|
10.9 | - | - | $ 3.67 B | USA |
 |
Agios Pharmaceuticals
AGIO
|
12.5 | $ 28.85 | -1.2 % | $ 1.67 B | USA |
 |
Champions Oncology
CSBR
|
1.13 | $ 5.98 | -1.48 % | $ 81.7 M | USA |
 |
Advaxis
ADXS
|
5.93 | - | -9.65 % | $ 45.9 M | USA |
 |
Akouos
AKUS
|
6.18 | - | 0.23 % | $ 488 M | USA |
 |
Завод ДИОД
DIOD
|
8.75 | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
0.454 | - | - | - | Russia |
 |
Albireo Pharma
ALBO
|
2.39 | - | -0.23 % | $ 916 M | USA |
 |
Cellectis S.A.
CLLS
|
1.52 | $ 3.71 | -2.43 % | $ 116 M | France |
 |
Alector
ALEC
|
1.12 | $ 2.13 | -3.39 % | $ 219 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
2.19 | - | 3.16 % | $ 1.9 M | USA |
 |
Aileron Therapeutics
ALRN
|
7.98 | - | 10.36 % | $ 9.8 M | USA |
 |
Altimmune
ALT
|
8.82 | $ 4.22 | 1.32 % | $ 300 M | USA |
 |
Teligent, Inc.
TLGT
|
1.92 | - | -13.85 % | $ 16.1 M | USA |
 |
AlloVir
ALVR
|
22.6 | - | 4.14 % | $ 49.1 M | USA |
 |
Viela Bio, Inc.
VIE
|
8.45 | - | - | $ 2.91 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
2.41 | - | -11.43 % | $ 502 K | USA |
 |
Amarin Corporation plc
AMRN
|
3.17 | $ 14.3 | 2.66 % | $ 5.93 B |  Irlanda |
 |
AbbVie
ABBV
|
3.18 | $ 233.44 | -0.33 % | $ 413 B | USA |